Biohaven Ltd is a biopharmaceutical company that focuses on developing innovative treatments for neurological and rare disorders. By harnessing advanced scientific research and drug development expertise, Biohaven aims to address unmet medical needs through their portfolio of promising therapies. The company's commitment to improving patient outcomes is reflected in their efforts to bring new, effective medications to market, particularly for conditions such as migraine and neurodegenerative diseases. Through rigorous clinical trials and a dedication to scientific excellence, Biohaven strives to enhance the quality of life for individuals affected by debilitating health issues. Read More
Curious to know what's happening on the US markets in the middle of the day on Wednesday? Join us as we explore the top gainers and losers in today's session.
The US market is yet to commence its session on Wednesday, but let's get a preview of the pre-market session and explore the top gainers and losers driving the early market movements.
As we await the opening of the US market on Monday, let's delve into the pre-market session and discover the top gainers and losers shaping the early market sentiment.
This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity scanner.
NEW YORK - September 12, 2025 ( NEWMEDIAWIRE ) - Levi & Korsinsky, LLP notifies investors in Biohaven Ltd. (NYSE: BHVN) of a class action securities lawsuit.
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Biohaven To Contact Him Directly To Discuss Their Options
The Law Offices of Frank R. Cruz reminds investors of the upcoming September 12, 2025 deadline to participate as a lead plaintiff in the securities fraud class action lawsuit filed on behalf of investors who acquired Biohaven Ltd. (“Biohaven” or the “Company”) (NYSE: BHVN) securities between March 24, 2023 and May 14, 2025, inclusive (the “Class Period”).
NEW YORK - September 11, 2025 ( NEWMEDIAWIRE ) - Levi & Korsinsky, LLP notifies investors in Biohaven Ltd. (NYSE: BHVN) of a class action securities lawsuit.
Bragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In Biohaven (BHVN) To Contact Him Directly To Discuss Their Options
NEW YORK, Sept. 10, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against Biohaven Ltd. (“Biohaven” or the “Company”) (NYSE: BHVN) and certain officers. The class action, filed in the United States District Court for the District of Connecticut, and docketed under 25-cv-01120, is on behalf of a class consisting of all persons and entities other than Defendants that purchased or otherwise acquired Biohaven securities between March 24, 2023 and May 14, 2025, both dates inclusive (the “Class Period”), seeking to recover damages caused by Defendants’ violations of the federal securities laws and to pursue remedies under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 sand Rule 10b-5 promulgated thereunder, against the Company and certain of its top officials.
